# Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

> **NCT05441826** · PHASE2 · TERMINATED · sponsor: **Tenet Medicines** · enrollment: 1 (actual)

## Conditions studied

- Minimal Change Disease
- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** VB119

## Key facts

- **NCT ID:** NCT05441826
- **Lead sponsor:** Tenet Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-03
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-10-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor change
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05441826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05441826, "Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05441826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*